Lag-3 and Gemcitabine for Treatment of Advanced Pancreas Cancer

NCT00732082 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

18

Enrollment

OTHER

Sponsor class

Stopped Company manufacturing study drug was unable to continue production.

Conditions

Pancreatic Neoplasms

Interventions

DRUG: Gemcitabine
BIOLOGICAL: LAG-3

Sponsor

Washington University School of Medicine